The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions

Journal of the American College of Cardiology

Volumn 32, Issue 5, 1998, Pages 1366-1370

  Steinhubl, Steven R ^a   Lauer, Michael S ^a   Mukherjee, Debabrata P ^a   Moliterno, David J ^a   Michael Lincoff, A ^a   Ellis, Stephen G ^a,b   Topol, Eric J ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TICLOPIDINE;

ADULT; ARTICLE; CORONARY ARTERY DISEASE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

BLOOD VESSEL PROSTHESIS IMPLANTATION; CORONARY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RISK FACTORS; STENTS; TICLOPIDINE; TIME FACTORS;

EID: 0032212314     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00376-3     Document Type: Article

References (31)

1. Simonton CA, Leon MB, Baim DS, et al. 'Optimal' directional coronary atherectomy. Final results of the Optimal Atherectomy Restenosis Study (OARS). Circulation 1998;97:332-9.
2. Abdelmeguid AE, Topol EJ. The myth of the myocardial "Infarctlet" during percutaneous coronary revascularization procedures. Circulation 1997;94:3369-75.
3. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998;31:241-51.
4. Kong TQ, Davidson CJ, Meyers SN, Tauke JT, Parker MA, Bonow RO. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA 1997;277:461-6.
5. Gurbel PA, Navetta FI, Bates ER, et al. Lesion-directed administration of tissue-plasminogen activator with intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplasty. Cathet Cardiovasc Diagn 1995;36:377-80.
6. Jorgensen L, Rowsell HC, Havig T, Glynn MF, Mustard JF. Adenosine diphosphate-induced platelet aggregation and myocardial infarction in swine. Lab Invest 1967;17:616-44.
7. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
8. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary interventions in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35.
9. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
10. The IMPACT II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary interventions. Lancet 1997;349:1422-8.
11. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial undergoing coronary angioplasty. Circulation 1997;96:1445-53.
12. Gawaz M, Neumann F-J, Ott I, May A, Rudiger S, Schomig A. Changes in membrane glycoproteins of circulating platelets after coronary stent implantation. Heart 1996;76:166-72.
13. Gawaz M, Neumann F-J, Ott I, May A, Schomig A. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. Circulation 1996;94:279-85.
14. Culip DE, Chauhan M, Lasorda D, et al. Influence of post-procedural myocardial infarction on late clinical outcome in the Stent Anti-Thrombotic Regimen Study (STARS) (abstr). Circulation 1997;94:1-31.
15. Alexander JH, Alexander K, Kong DE, Tung CY, Whellan D. Session highlights from the American Heart Association Scientific Sessions: November 9-12, 1997. Am Heart J 1998;135:160-7.
16. Schomig A, Neumann F-J, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronaryartery stents. N Engl J Med 1996;334:1084-9.
17. Rupprecht H-J, Darius H, Borkowski U, et al. Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation. Circulation 1998;97:1046-52.
18. De Caterina R, Sicari R, Bernini W, Lazzerini G, Strata GB, Giannessi D. Benefit/risk profile of combination antiplatelet therapy with ticlopidine and aspirin. Thromb Haemost 1991;65:504-10.
19. Kuzniar J, Splawinska B, Malinga K, Mazurek AP, Spawinski J. Pharmacodynamics of ticlopidine: relationship between dose and time administration to platelet inhibition. Int J Clin Pharm Ther 1996;34:357-61.
20. Mak K-H, Belli G, Ellis SG, Moliterno DJ. Subacute stent thrombosis: evolving issues and current concepts. J Am Coll Cardiol 1996;27:494-503.
21. Mantel N. Chi-square tests with one degree of freedom: extensions of the Mantel-Haenszel procedure. J Am Stat Assoc 1963;58:690-700.
22. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: Wiley, 1989.
23. Di Perri T, Pasini FL, Frigerio C, et al. Pharmacodynamics of ticlopidine in man in relation to plasma and blood cell concentration. Eur J Clin Pharmacol 1991;41:429-34.
24. Hardisty RM, Fowling MJ, Nokes TJC. The action of ticlopidine on human platelets: studies on aggregation, secretion, calcium mobilization and membrane glycoproteins. Thromb Haemost 1990;65:186-90.
25. Humbert M, Nurden P, Bihour C, et al. Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation. Arterioscler Thromb Vase Biol 1996;16:1532-43.
26. Herbert JM, Bernat A, Samama M, Maffrand JP. The antiaggregating and antithrombotic activity of ticlopidine is potentiated by aspirin in the rat. Thromb Haemost 1996;76:94-8.
27. Bossavy J-P, Thalamas C, Sagnard L, Barret A, Sakariassen K, Boneu B. A double-blind randomised comparison of combined ticlopidine and aspirin therapy vs ticlopidine or aspirin alone on experimental arterial thrombogenesis in man (abstr). Circulation 1997;96:I-722.
28. Gregorini L, Marco J, Fajadet J, et al. Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilitation procedures. J Am Coll Cardiol 1997;29:13-20.
29. van de Loo A, Nauck M, Noory E, Just H, Wollschlager H. Enhancement of platelet inhibition of ticlopidine plus aspirin vs aspirin alone given prior to elective PTCA. Eur Heart J 1998;19:96-102.
30. Tschoepe D, Schultheiss HP, Kolarov P, et al. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 1993;88:37-42.
31. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 1996;94:1528-36.